Naoki Hosen

Summary

Affiliation: Osaka University
Country: Japan

Publications

  1. ncbi Multiple myeloma-initiating cells
    Naoki Hosen
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7 Yamada oka, Suita, Osaka, 565 0871, Japan
    Int J Hematol 97:306-12. 2013
  2. ncbi CD48 as a novel molecular target for antibody therapy in multiple myeloma
    Naoki Hosen
    Department of Cancer Stem Cell Biology Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Br J Haematol 156:213-24. 2012
  3. ncbi CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
    Naoki Hosen
    Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305 5323, USA
    Proc Natl Acad Sci U S A 104:11008-13. 2007
  4. ncbi Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells
    Naoki Hosen
    Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
    Stem Cells 25:1635-44. 2007
  5. ncbi Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    Yoshihiro Oka
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka 565 0871, Japan
    Proc Natl Acad Sci U S A 101:13885-90. 2004
  6. ncbi High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ
    Ayako Murao
    Department of Respiratory Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 101:848-54. 2010
  7. ncbi WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide
    Yoshihiro Oka
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    Anticancer Agents Med Chem 9:787-97. 2009
  8. ncbi WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
    Yusuke Oji
    Department of Cancer Stem Cell Biology Respiratory Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Haematol 85:358-60. 2010
  9. ncbi CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion
    Noriyuki Kijima
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan
    Neuro Oncol 14:1254-64. 2012
  10. ncbi A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination
    Fumihiro Fujiki
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7, Yamada oka, Suita City, Osaka 565 0871, Japan
    Anticancer Res 30:2247-54. 2010

Detail Information

Publications50

  1. ncbi Multiple myeloma-initiating cells
    Naoki Hosen
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7 Yamada oka, Suita, Osaka, 565 0871, Japan
    Int J Hematol 97:306-12. 2013
    ..An improved understanding of how the bone marrow microenvironment supports MM-initiating plasma cells, which can initiate MM disease in the SCID-hu (or rab) model, is thus now essential...
  2. ncbi CD48 as a novel molecular target for antibody therapy in multiple myeloma
    Naoki Hosen
    Department of Cancer Stem Cell Biology Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Br J Haematol 156:213-24. 2012
    ..These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM...
  3. ncbi CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
    Naoki Hosen
    Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305 5323, USA
    Proc Natl Acad Sci U S A 104:11008-13. 2007
    ..These results demonstrate that CD96 is a cell surface marker present on many AML-LSC and may serve as an LSC-specific therapeutic target...
  4. ncbi Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells
    Naoki Hosen
    Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
    Stem Cells 25:1635-44. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  5. ncbi Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    Yoshihiro Oka
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka 565 0871, Japan
    Proc Natl Acad Sci U S A 101:13885-90. 2004
    ..It was therefore demonstrated that WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in cancer regression without damage to normal tissues...
  6. ncbi High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ
    Ayako Murao
    Department of Respiratory Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 101:848-54. 2010
    ..These results should provide us with an insight into WT1-specific immune response in tumor-bearing patients and give us an idea of enhancement of clinical response in WT1 protein-targeted immunotherapy...
  7. ncbi WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide
    Yoshihiro Oka
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    Anticancer Agents Med Chem 9:787-97. 2009
    ..WT1 peptide vaccination in an "adjuvant setting" should be considered a promising treatment to protect against progression or relapse of malignancies in cases with minimal residual disease...
  8. ncbi WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
    Yusuke Oji
    Department of Cancer Stem Cell Biology Respiratory Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Haematol 85:358-60. 2010
    ..The case presented here indicates that WT1 peptide vaccine may become a safe and cure-oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib...
  9. ncbi CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion
    Noriyuki Kijima
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan
    Neuro Oncol 14:1254-64. 2012
    ..In summary, we were able to show that ALCAM constitutes a novel glioblastoma progenitor cell marker. We could also demonstrate that ALCAM and its soluble isoform are involved in the regulation of glioblastoma invasion and progression...
  10. ncbi A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination
    Fumihiro Fujiki
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7, Yamada oka, Suita City, Osaka 565 0871, Japan
    Anticancer Res 30:2247-54. 2010
    ..From this study we concluded that occurrence of WT1(332)-specific Th response could predict good clinical response of WT1 CTL epitope vaccination...
  11. ncbi Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer
    Yusuke Oji
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    Cancer Sci 94:606-11. 2003
    ..These findings indicate an important role of the wild-type WT1 gene in the tumorigenesis of primary thyroid cancer...
  12. ncbi Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
    Yoshihiro Oka
    Department of Molecular Medicine, Osaka University Medical School, Suita City, Osaka, Japan
    Int J Hematol 78:56-61. 2003
    ..These results have provided us with the first clinical evidence suggesting that WT1 peptide-based immunotherapy is an attractive treatment for patients with leukemias or MDS...
  13. ncbi Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration
    Hiroko Nakajima
    Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
    Vaccine 30:722-9. 2012
    ..WT1 peptide vaccination combined with IFN-β administration can thus be expected to enhance the clinical efficacy of WT1 immunotherapy...
  14. ncbi AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
    Sumiyuki Nishida
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, 1-7, Yamada-oka, Suita City, Osaka 565-0871, Japan
    Blood 107:3303-12. 2006
    ..These results demonstrate that AML1-ETO may exert its leukemogenic function in cooperation with the expression of WT1...
  15. ncbi Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1)
    Hiroya Tamaki
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan
    Int J Hematol 78:349-56. 2003
    ..In conclusion, this RQ-PCR method is convenient and reliable for monitoring MRD and enables routine clinical use of a WT1 assay...
  16. ncbi The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
    Hiroyasu Ogawa
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Japan
    Blood 101:1698-704. 2003
    ..These findings strongly suggest that the WT1 assay is very useful for the prediction and management of relapse following allogeneic stem cell transplantation regardless of the presence of chimeric gene markers...
  17. ncbi Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma
    Yasuyoshi Chiba
    Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565 0871, Japan
    Jpn J Clin Oncol 40:395-403. 2010
    ..To address this issue, we investigated the changes in frequency and number of WT1-specific T-cells in patients with malignant gliomas...
  18. ncbi Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope
    Zheyu Li
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Microbiol Immunol 52:551-8. 2008
    ..The present results should help to broaden the application of WT1 peptide-based immunotherapy from only HLA-A 0201-positive to HLA-A 0206-positive cancer patients as well...
  19. ncbi Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors
    Yusuke Oji
    Department of Bioinformatics, Osaka University Graduate School of Medicine, 1 7 Yamada oka, Suita, Osaka 565 0871, Japan
    Cancer Sci 95:822-7. 2004
    ..These results may indicate that the W T1 gene plays an important role in tumorigenesis of primary astrocytic tumors...
  20. ncbi Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma
    Akihiro Tsuboi
    Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 1 7 Yamada oka, Suita City, Osaka, Japan
    Int J Hematol 86:414-7. 2007
    ....
  21. ncbi WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers
    Yoshihiro Oka
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Japan
    ScientificWorldJournal 7:649-65. 2007
    ....
  22. ncbi Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma
    Yusuke Oji
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    Cancer Sci 94:712-7. 2003
    ..These results may indicate an important role of the wild-type WT1 gene in tumorigenesis of colorectal adenocarcinoma...
  23. ncbi WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases
    Akihiro Tsuboi
    Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Japan
    Microbiol Immunol 48:175-84. 2004
    ..These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer...
  24. ncbi "Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development
    Yoshihiro Oka
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2 2, Yamada oka, Suita City, Osaka 565 0871, Japan
    Curr Med Chem 15:3052-61. 2008
    ..Other modalities, including gene therapy using genes encoding WT1-specific T cell receptor or DNA vaccination, are also expected to be developed...
  25. ncbi Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer
    Yusuke Oji
    Department of Functional Diagnostic Science, Surgical Oncology, Molecular Medicine and Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Jpn J Clin Oncol 34:74-7. 2004
    ..CONCLUSION: The results indicate that the wild-type WT1 gene plays an important role in the tumorigenesis of primary breast cancer...
  26. ncbi WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
    Takashi Miyatake
    Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2 2, Yamadaoka, Suita, Osaka 565 0871, Japan
    J Cancer Res Clin Oncol 139:457-63. 2013
    ..The aim of the present study was to analyze the long-term survival effects of WT1 peptide vaccine, in addition to its anti-tumor effects and toxicity...
  27. ncbi Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors
    Soyoko Morimoto
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 103:408-14. 2012
    ..These results should provide us with a novel insight for a better understanding of WT1-specific immune responses...
  28. ncbi Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies
    Yukie Tanaka-Harada
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 101:594-600. 2010
    ..These findings represent a novel insight for a better understanding of WT1-specific immune response...
  29. ncbi The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model
    Tatsuya Fujioka
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2, Yamada-oka, Suita City, 565-0871, Osaka, Japan
    Transpl Immunol 11:187-95. 2003
    ..Thus, the size of the T cell dose is one of the important considerations in tolerance induction, GVHD and rejection...
  30. ncbi Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor
    Taichi Tamanaka
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7, Yamada oka, Suita City, Osaka 565 0871, Japan
    Anticancer Res 32:5201-9. 2012
    ..These results provided us, for the first time at molecular basis, with a proof-of-concept of modified WT1(235) peptide-based immunotherapy for natural WT1(235) peptide-expressing malignancies...
  31. ncbi Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
    Tanyarat Jomgeow
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita, Osaka 565-0871, Japan
    Cancer Sci 97:259-70. 2006
    ..The present results may provide a novel insight into the signaling pathway of the WT1 gene for its oncogenic functions...
  32. ncbi Overexpression of the Wilms' tumor gene WT1 in esophageal cancer
    Yusuke Oji
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1 7, Yamada oka, Suita, Osaka 565 0871, Japan
    Anticancer Res 24:3103-8. 2004
    ..The Wilms' tumor gene WT1 is overexpressed in various kinds of solid cancers. However, it remains unclear whether WT1 is expressed in esophageal squamous cell carcinoma...
  33. ncbi Functional human Th17 clones with WT1-specific helper activity
    Sho Tachino
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka, Japan
    Cancer Immunol Immunother 62:801-10. 2013
    ..Th17 clones established here and the method to establish antigen-specific Th17 clones should be a useful tool to further analyze the roles of human Th17 in tumor immunity...
  34. ncbi The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver
    Keisuke Kanato
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Biochem Biophys Res Commun 326:836-43. 2005
    ..These results indicated that WT1 expression is a common marker of both hepatocyte and endothelial progenitors. These results also implied a role of the WT1 gene in lineage determination...
  35. ncbi The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells
    Hanfen Li
    Departments of Clinical Laboratory Science, Osaka University Medical School, Suita City, Osaka, Japan
    Int J Hematol 77:463-70. 2003
    ..These results are the first direct evidence demonstrating that the WT1 gene is involved in the development and differentiation of T-lineage cells...
  36. ncbi WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer
    Toshiaki Shirakata
    Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
    Anticancer Res 32:1081-5. 2012
    ..These results indicate the potential of WT1 peptide-based immunotherapy for the treatment of chemotherapy-resistant salivery gland cancer...
  37. ncbi Self-renewal of the long-term reconstituting subset of hematopoietic stem cells is regulated by Ikaros
    Peter Papathanasiou
    Institute of Stem Cell Biology and Regenerative Medicine, and Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA
    Stem Cells 27:3082-92. 2009
    ....
  38. ncbi Expression of AA4.1 marks lymphohematopoietic progenitors in early mouse development
    Toshiyuki Yamane
    Department of Pathology, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 106:8953-8. 2009
    ..These data suggest that AA4.1 is a cell surface marker that can identify the earliest lymphohematopoietic progenitors in mouse development...
  39. ncbi HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells
    Yuhung Lin
    Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    J Immunother 36:159-70. 2013
    ..Thus, these results demonstrated the feasibility of immunotherapy based on adoptive transfer of WT1332-specific TCR-transduced CD4+ T cells for the treatment of leukemia...
  40. ncbi Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
    Akihiro Tsuboi
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
    Cancer Immunol Immunother 51:614-20. 2002
    ..Therefore, cancer immunotherapy using this modified 9-mer WT1 peptide should provide efficacious treatment for HLA-A*2402-positive patients with leukemias and solid tumors...
  41. ncbi Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas
    Takafumi Ueda
    Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka
    Cancer Sci 94:271-6. 2003
    ....
  42. ncbi Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation
    Hiroyasu Ogawa
    Departments of Molecular Medicine, and Clinical Laboratory Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Transplantation 74:236-43. 2002
    ..To address this problem, we examined the efficacy of FK506-plus-MTX-plus-methylprednisolone (mPSL) in 20 patients who underwent BMT from unrelated donors...
  43. ncbi WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor
    Yusuke Oji
    Department of Biomedical Informatics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Int J Cancer 125:381-7. 2009
    ..These results also suggested that WT1-specific immune responses played an important role in anti-cancer immunity in NSCLC...
  44. ncbi Transcriptional profiling of antigen-dependent murine B cell differentiation and memory formation
    Deepta Bhattacharya
    Institute of Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Immunol 179:6808-19. 2007
    ....
  45. ncbi Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle
    Junya Nakamura
    Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565 0871, Japan
    Int J Oncol 34:1181-9. 2009
    ....
  46. ncbi Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells
    Naoki Hosen
    Department of Molecular Medicine, Osaka University Medical School, Osaka, Japan
    Br J Haematol 116:409-20. 2002
    ..Our results could indicate that these WT1-expressing CD34+ BM cells were normal counterparts of leukaemia cells...
  47. ncbi Solitary right ventricle metastasis by renal cell carcinoma
    Mitsuru Masaki
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
    J Am Soc Echocardiogr 17:397-8. 2004
    ..This case highlights the need to consider an underlying neoplastic syndrome in patients presenting isolated right ventricle mass by echocardiography...
  48. ncbi Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers
    Yusuke Oji
    Department of Clinical Laboratory Science, Osaka University Medical School, Suita City, Osaka, Japan
    Int J Cancer 100:297-303. 2002
    ....
  49. ncbi Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
    Olga A Elisseeva
    Department of Radiation Biology, Osaka University Medical School, Japan
    Blood 99:3272-9. 2002
    ..Our findings may provide new insight into the rationale for elicitation of cytotoxic T-cell responses against the WT1 protein in cancer immunotherapy using the WT1 vaccine...
  50. ncbi Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation
    Hiroyasu Ogawa
    Transplantation 78:488-9. 2004